Jing Shan Lim

TL;DR: This first comprehensive study of somatic genome alterations in SCLC uncovers several key biological processes and identifies candidate therapeutic targets in this highly lethal form of cancer.

TL;DR: The protumorigenic and tumor-suppressive functions of Notch signaling are discussed, and the molecular mechanisms that underlie these functions in hematopoietic cancers and solid tumors are dissected.

TL;DR: Disruption of the interaction of CD47 with SIRPα using anti-CD47 antibodies induced macrophage-mediated phagocytosis of human SCLC patient cells in culture, and this approach could enable personalized immunotherapeutic regimens in patients with S CLC and other cancers.

TL;DR: It is shown that Notch signalling can be both tumour suppressive and pro-tumorigenic in small-cell lung cancer, and the presence of these cells may serve as a biomarker for the use of Notch pathway inhibitors in combination with chemotherapy in select patients with small- cell lung cancer.

TL;DR: The identification of widespread chromatin changes during SCLC progression reveals an unexpected global reprogramming during metastatic progression, and indicates that Nfib is necessary and sufficient to increase chromatin accessibility at a large subset of the intergenic regions.